Both losartan and enalapril produced a significant reduction of markers of metabolic syndrome and may be regarded as effective drugs for treatment of hypertension in patients with markers of metabolic syndrome.
Peptic ulcers are best treated by proton pump inhibitors (PPIs), however, other simple gastrointestinal (GIT) disorders should be better treated by other acid neutralizing or anti-secretory agents. Unfortunately, most GIT diseases were reported to be treated by PPIs even though non-indicated cases. The reasons might include ease availability with/without prescription, reduce patient awareness, and overprescription of PPIs by the health care professionals. This study aims to highlight the effect of these drugs on the renal function test. Patients were recruited and enrolled in the study from outpatients private clinics and plasma samples were withdrawn from control healthy, esomeprazole and omeprazole users individuals. Plasma samples were frozen for further analysis, creatinine and urea test were conducted on overall samples and the results were displayed confirming significant dysfunctioning of the renal system from PPIs use. The study concluded that creatinine and urea are higher in a patient on esomeprazole than omeprazole and the control group. The study recommends general awareness of the society about regular use of these medications unless otherwise carefully required.
The pathogenesis of essential hypertension through the interaction with elements of the rennin angiotensin aldosterone system is affected by oxidative stress and inflammation. The present study aimed to assess the effects of ACE-Inhibitor, lisinopril, on blood pressure, lipid profiles (total cholesterol, triglycerides, LDL and HDL), MDA, and TAS, hsCRP, and serum leptin levels n hypertensive patients. A case control study included 100 newly diagnosed mild to moderate hypertensive patients and another 100 apparently healthy aged and sex matched subjects as controls. The patients were treated with 10 mg lisinopril orally per day for three months’ duration. Venous blood sample was taken to test levels of MDA, GSH and TAS, hsCRP, lipid profiles and leptin in the serum before and after lisinopril therapy for both patients and controls. Systolic and diastolic blood pressure were also assessed before and after lisinopril therapy for both patients and controls. In hypertensive patients treated with lisinopril, markers of oxidative stress (MDA, TAS and GSH), high sensitive C-reactive protein and leptin were all found to be decreased significantly after drug treatment (p < 0.01). Lisinopril affectively lowered systolic and diastolic BP values (p < 0.01). A significant decrease in lipid profile (p < 0.01) with a significant increase in HDL-C and TAS levels (p < 0.01) were found in lisinopril treated group in comparison with their values before treatment. Lisinopril may be used as a treatment for high blood pressure, as well as for the insulin resistance, hyperleptinemic, and low-grade inflammatory states that are associated with the disease.
Introduction:Coronavirus pandemic is currently a global health concern with no established treatment guidelines. The aim of the present study was to determine the therapeutic effectiveness of hydroxychloroquine combined with azithromycin in patients with positive coronavirus disease 2019 (COVID-19) admitted to the hospital with severe dyspnea, as well as the incidence of occurrence of adverse effects.Methods: It was intended to utilize a retrospective clinical study of approximately 250 adult patients admitted to the ALSALAM Teaching Hospital in Mosul city with mild to moderate COVID-19 in order to evaluate treatment efficacy in combination with clinical and biochemical findings. Two groups were involved in the research. The first patient group consisted of 250 people who got hydroxychloroquine in conjunction with azithromycin, while the second untreated control group consisted of 100 individuals who received no medication as part of the research.Results: Baseline parameters (clinical and biochemical assays) did not vary substantially among the two groups. Patients in the treatment group were hospitalized at a rate of 30%, compared to 27% in the untreated control group (P<0.001). Between groups, there were no statistically significant changes in mortality, non-invasive oxygen demand, or hospitalization duration. Biochemical and Clinical outcomes were comparable between those receiving hydroxychloroquine with azithromycin and those do not receive any medication. Conclusion: This treatment regimen was shown to be not affective in mild to severe positve COVID-19 hospitalized patients and was associated with a small number of mild to moderate clinical adverse effects.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.